About: Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts
Creator	Raffaele, San Aranda, Enrique Bongiovanni, Lucia De La Haba-Rodríguez, Juan Díaz, Cesar Guil-Luna, Silvia Guler, Ipek Khouadri, Karima Lm, López-Sánchez Mantrana, Ana María López-Sánchez, Laura Medina-Fernández, Francisco Mena, Rafael Menter, Thomas Navarrete-Sirvent, Carmen Rodríguez-Ariza, Antonio Toledano-Fonseca, Marta Tornillo, Luigi Villar, Carlos
source	PMC
abstract	Tumor budding has been found to be of prognostic significance for several cancers, including colorectal cancer (CRC). Additionally, the molecular classification of CRC has led to the identification of different immune microenvironments linked to distinct prognosis and therapeutic response. However, the association between tumor budding and the different molecular subtypes of CRC and distinct immune profiles have not been fully elucidated. This study focused, firstly, on the validation of derived xenograft models (PDXs) for the evaluation of tumor budding and their human counterparts and, secondly, on the association between tumor budding and the immune tumor microenvironment by the analysis of gene expression signatures of immune checkpoints, Toll-like receptors (TLRs), and chemokine families. Clinical CRC samples with different grades of tumor budding and their corresponding PDXs were included in this study. Tumor budding grade was reliably reproduced in early passages of PDXs, and high-grade tumor budding was intimately related with a poor-prognosis CMS4 mesenchymal subtype. In addition, an upregulation of negative regulatory immune checkpoints (PDL1, TIM-3, NOX2, and IDO1), TLRs (TLR1, TLR3, TLR4, and TLR6), and chemokine receptors and ligands (CXCR2, CXCR4, CXCL1, CXCL2, CXCL6, and CXCL9) was detected in high-grade tumor budding in both human samples and their corresponding xenografts. Our data support a close link between high-grade tumor budding in CRC and a distinctive immune-suppressive microenvironment promoting tumor invasion, which may have a determinant role in the poor prognosis of the CMS4 mesenchymal subtype. In addition, our study demonstrates that PDX models may constitute a robust preclinical platform for the development of novel therapies directed against tumor budding in CRC.
has issue date	2020-07-03(xsd:dateTime)
bibo:doi	10.3389/fmed.2020.00264
has license	cc-by
sha1sum (hex)	6b0f099eeefb67353f25d353b5a5ec3332da0fdb
schema:url	https://doi.org/10.3389/fmed.2020.00264
resource representing a document's title	Association of Tumor Budding With Immune Evasion Pathways in Primary Colorectal Cancer and Patient-Derived Xenografts
has PubMed Central identifier	PMC7347987
schema:publication	Front Med (Lausanne)
resource representing a document's body	covid:6b0f099eeefb67353f25d353b5a5ec3332da0fdb#body_text
is schema:about of	named entity 'TLR1' named entity 'human' named entity 'reliably' named entity 'samples' named entity 'study' named entity 'gene' named entity 'microenvironments' named entity 'focused' named entity 'subtypes' named entity 'expression' named entity 'Colorectal Cancer' named entity 'Immune' named entity 'TLR4' named entity 'CLINICAL' named entity 'NEGATIVE' named entity 'DETERMINANT' named entity 'CXCL2' named entity 'CXCL9' named entity 'STUDY' named entity 'GRADES' named entity 'ROLE' named entity 'CXCR4' named entity 'tumor' named entity 'immune' named entity 'grade' named entity 'immune' named entity 'colorectal cancer' named entity 'PDX' named entity 'prognosis' named entity 'prognostic' named entity 'human' named entity 'grades' named entity 'PDXs' named entity 'immune' named entity 'immune' named entity 'ligands' named entity 'tumor' named entity 'tumor' named entity 'chemokine receptors' named entity 'tumor' named entity 'mesenchymal' named entity 'xenografts' named entity 'CXCL6' named entity 'CXCL1' named entity 'PDXs' named entity 'PDXs' named entity 'tumor' named entity 'Colorectal Cancer' named entity 'Xenografts' named entity 'DFS' named entity 'Histopathological' named entity 'gene expression' named entity 'variable selection' named entity 'incubation' named entity 'solid tumors' named entity 'TLR3' named entity 'stroma' named entity 'tumor' named entity 'colon cancer' named entity '10.7' named entity 'tumor' named entity 'mesenchymal' named entity 'tumor' named entity 'stroma' named entity 'prognostic significance'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software